PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
15
02
2021
accepted:
21
07
2021
revised:
24
05
2021
pubmed:
8
8
2021
medline:
20
8
2022
entrez:
7
8
2021
Statut:
ppublish
Résumé
Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to enhance our characterization of advanced prostate cancer and further enable precision oncology. The Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) is a consortium whose aims are to establish a repository of de-identified clinical and genomic patient data that are linked to patient outcomes. The consortium structure includes a (1) bio-informatics committee to standardize genomic data and provide quality control, (2) biostatistics committee to independently perform statistical analyses, (3) executive committee to review and select proposals of relevant questions for the consortium to address, (4) diversity/inclusion committee to address important clinical questions pertaining to racial disparities, and (5) patient advocacy committee to understand patient perspectives to improve patients' quality of care. The PROMISE consortium was formed by 16 academic institutions in early 2020 and a secure RedCap database was created. The first patient record was entered into the database in April 2020 and over 1000 records have been entered as of early 2021. Data entry is proceeding as planned with the goal to have over 2500 patient records by the end of 2021. The PROMISE consortium provides a powerful clinical-genomic platform to interrogate and address data gaps that have arisen with increased genomic testing in the clinical management of prostate cancer. The dataset incorporates data from patient populations that are often underrepresented in clinical trials, generates new hypotheses to direct further research, and addresses important clinical questions that are otherwise difficult to investigate in prospective studies.
Identifiants
pubmed: 34363009
doi: 10.1038/s41391-021-00433-1
pii: 10.1038/s41391-021-00433-1
pmc: PMC9385488
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
388-396Subventions
Organisme : NCI NIH HHS
ID : P50 CA186786
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2019 Feb 10;37(5):403-410
pubmed: 30576268
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Urol Oncol. 2020 Mar;38(3):79.e15-79.e22
pubmed: 31522863
Cancers (Basel). 2017 Apr 15;9(4):
pubmed: 28420128
J Natl Compr Canc Netw. 2019 May 1;17(5):515-521
pubmed: 31085765
JCO Precis Oncol. 2020;4:382-392
pubmed: 32671317
J Clin Invest. 2018 Oct 1;128(10):4441-4453
pubmed: 30179225
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
PLoS One. 2020 May 26;15(5):e0233260
pubmed: 32453797
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
J Urol. 2019 Feb;201(2):259-267
pubmed: 30218761
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Eur Urol. 2019 Mar;75(3):378-382
pubmed: 30337059
Eur Urol Focus. 2016 Dec;2(5):532-539
pubmed: 28723519
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Urol Oncol. 2020 Mar;38(3):80.e1-80.e7
pubmed: 31630993
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Eur Urol. 2020 Nov;78(5):671-679
pubmed: 32317181
J Nucl Med. 2021 May 10;62(5):695-699
pubmed: 32978283
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
BJU Int. 2019 Nov;124 Suppl 1:5-13
pubmed: 31638341
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
J Clin Oncol. 2017 Jul 10;35(20):2251-2259
pubmed: 28489509
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Eur Urol. 2016 Jun;69(6):992-5
pubmed: 26724258
Eur Urol. 2017 Feb;71(2):151-154
pubmed: 27477525
Clin Cancer Res. 2020 Jul 1;26(13):3230-3238
pubmed: 32220891
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Eur Urol. 2019 Jan;75(1):184-192
pubmed: 30340782
JCO Precis Oncol. 2020;4:355-366
pubmed: 32856010
J Natl Cancer Inst. 2019 Mar 1;111(3):245-255
pubmed: 30856272
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
N Engl J Med. 2020 Sep 10;383(11):1083-1085
pubmed: 32905685
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Clin Cancer Res. 2020 Mar 1;26(5):1114-1125
pubmed: 31744831
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Cell. 2018 Jul 12;174(2):433-447.e19
pubmed: 29909985